Argenx (ARGX) has released an update.
Argenx SE has announced the approval of VYVGART for adult patients with Primary Immune Thrombocytopenia (ITP) in Japan, marking the first global approval for this indication. The approval was based on the positive results from the global Phase 3 ADVANCE-IV trial, showing a significant improvement in platelet counts for patients with chronic ITP. VYVGART, an IgG1 antibody fragment designed to reduce circulating IgG autoantibodies, is already approved for the treatment of generalized myasthenia gravis in multiple regions.
For further insights into ARGX stock, check out TipRanks’ Stock Analysis page.
